ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups
Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.
Related Articles
World Cancer Day 2025: International Journal of Cancer
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
17th Annual Hematologic Malignancies Demystified 2025 | Virtual
Register now for HMD 2025 and explore groundbreaking advancements in hematology. Stay informed with the latest innovations shaping the future of hematology research presented at…
China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer
Enfortumab vedotin-efjv plus has received NMPA approval for patients with locally advanced or metastatic urothelial cancer.
Is Age a Prognostic Factor in Cervical Cancer?
Researchers found that age was not associated with recurrence-free survival or overall survival.
Fixed-Duration Zanubrutinib/Venetoclax Shows Efficacy in R/R Chronic Lymphocytic Leukemia
Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.
FDA Issues Draft Guidance for Accelerated Approval Confirmatory Clinical Trials
The FDA released a draft guidance document detailing their interpretation of when a confirmatory clinical trial for an accelerated approval is underway.
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.
Ohio State to partner with Zangmeister Cancer Center to expand access to cancer care
The OSUCCC – James announces today it will form a new partnership with Zangmeister Cancer Center, a partner practice of American Oncology Network. This
Episode 180: Reducing the Pain of Cancer Patients, with Dr. Whitney Luke
The James Cancer Hospital is a leader is helping cancer patients deal with the pain that can be associated with treatment. “Our inpatient oncology rehabilitation…
TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC
Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma